ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
Darren J WongMargaret LittlejohnRosalind EdwardsKathy JacksonPeter RevillAnuj GaggarKathryn KitrinosMani SubramanianPatrick MarcellinMaria Buti-FerretHarry JanssenEd GaneStephen LocarniniAlexander ThompsonPublished in: Liver international : official journal of the International Association for the Study of the Liver (2018)
In genotype A subjects undergoing long-term NA therapy, ALT flares predict for HBsAg response. The delay between ALT flare and HBsAg loss has implications for clinical trial design for early phase development of immunomodulatory strategies aiming for HBsAg loss.